Robert Driscoll

SVP, Equity Research at Wedbush Securities
On the record
Represented by:

Robert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Achaogen (AKAO), Arbutus Biopharma (ABUS), Nabriva Therapeutics (NBRV), and Sierra Oncology (SRRA).

Adicet Bio, Inc. (ACET)
Alpine Immune Sciences (ALPN)
Arcus Biosciences Inc. (RCUS)
Arcus Biosciences Inc. (RCUS)
Arvinas Inc (ARVN)
Atreca, Inc. (BCEL)
Black Diamond Therapeutics, Inc. (BDTX)
Cidara Therapeutics (CDTX)
Cyteir Therapeutics, Inc. (CYT)
CytomX Therapeutics (CTMX)
Day One Biopharmaceuticals Inc. (DAWN)
Elevation Oncology (ELEV)
Entasis Therapeutics (ETTX)
Foghorn Therapeutics (FHTX)
Harpoon Therapeutics (HARP)
Ideaya Biosciences (IDYA)
IGM Biosciences, Inc. (IGMS)
Kura Oncology (KURA)
Omega Therapeutics (OMGA)
Replimune Group Inc (REPL)
Surface Oncology, Inc. (SURF)
Tango Therapeutics, Inc. (TNGX)
Zentalls Pharmaceuticals, Inc. (ZNTL)

Recent Quotes
Sign up to view all
  • They tend to be more volatile when there’s a downturn.

Sign up to view all